Pharmaceutical Executive Daily: Amplitude Therapeutics Partners with Eli Lilly

Amplitude Therapeutics and Chai Discovery ink AI and RNA collaborations with Eli Lilly and Bristol Myers Squibb, Norstella's Dan Chancellor makes the case for dealmaking as a survival skill, and this week's rare disease approvals and a $322 million biosimilar deal reveal where pharma strategy is heading.